China’s humanoid robot IPO slowdown no threat to firms with ‘genuine strength’: Deloitte
The market is shifting from a ‘blind rush’ to ‘fine screening’, but funding is still there for firms with clear strategies, Deloitte China says
Beijing’s recent tightening of approvals for humanoid robot makers seeking initial public offerings (IPOs) poses no threat to companies with clear commercialisation strategies, as funding channels remain wide open for qualified players, according to Deloitte China.
“Market funds are shifting from the ‘blind rush’ of the past to ‘fine screening’,” said Dick Kay, Deloitte China’s capital market services group national leader, at a press conference on Thursday.
Investors and regulators now placed more weight on whether companies had sustainable revenue growth, core technological barriers and real-world application scenarios, he added.